England’s National Health Service (NHS) is set to expand its treatment options for chronic heart failure (CHF) with the National Institute for Health and Care Excellence (NICE) recommending Bayer’s novel non-steroidal mineralocorticoid receptor antagonist (MRA), Kerendia (finerenone), for patients suffering from preserved or mildly reduced ejection fraction. This pivotal decision, anticipated to be formally adopted in final draft guidance expected in August 2026, marks a significant advancement in managing a condition that remains a leading cause of preventable hospital admissions across the nation. The recommendation signifies a crucial step towards alleviating the substantial burden of heart failure on both patients and the healthcare system.
Background: The Pervasive Challenge of Heart Failure
Heart failure is a chronic and progressive condition where the heart muscle cannot pump blood as well as it should. This can lead to a range of debilitating symptoms, including shortness of breath, fatigue, and swelling in the legs and ankles. In England, an estimated 635,000 individuals are living with heart failure, a figure that underscores the scale of the public health challenge. A significant proportion of these patients, approximately half, have preserved or mildly reduced ejection fraction, a subtype of the condition where the heart’s lower left chamber (left ventricle) does not contract effectively, but the amount of blood it pumps out with each beat remains relatively normal.
The impact of heart failure extends beyond individual suffering, contributing significantly to healthcare resource utilization. Between 2023 and 2024 alone, heart failure was linked to an alarming 100,000 hospitalisations in England. Many of these admissions are deemed avoidable, highlighting a critical need for more effective preventative measures and treatment strategies. This statistic underscores the importance of the NICE recommendation for Kerendia, which aims to address this gap by offering a new therapeutic avenue for a substantial patient cohort.
Kerendia’s Mechanism of Action and Unique Advantages
Kerendia’s therapeutic efficacy in treating heart failure with preserved or mildly reduced ejection fraction stems from its distinct mechanism of action. As a non-steroidal MRA, it targets the mineralocorticoid receptor, a key player in the pathological processes that contribute to heart failure progression. Unlike traditional steroidal MRAs, Kerendia’s non-steroidal structure offers a critical advantage by mitigating some of the well-known side effects associated with this class of drugs.
The drug works by reducing vascular inflammation and the detrimental scarring within the heart muscle that is often induced by mineralocorticoid signaling. This process, known as fibrosis, stiffens the heart muscle and impairs its ability to relax and fill with blood efficiently. Furthermore, Kerendia contributes to managing heart failure by reducing sodium retention in the kidneys. Excessive sodium can lead to fluid accumulation, increasing the workload on the heart as it attempts to pump the excess fluid throughout the body. By promoting the excretion of sodium, Kerendia helps to alleviate this fluid overload, thereby reducing the strain on the heart.
A key distinction of Kerendia compared to existing MRAs available through the NHS, such as spironolactone and eplerenone (generics of Pfizer-developed drugs), lies in its non-steroidal nature. This characteristic allows Kerendia to be prescribed to a broader patient population without the same concerns about potential side effects related to sex hormone activity. Bayer has also engineered Kerendia for enhanced selectivity, aiming to further minimize off-target effects and improve the overall safety profile. This enhanced selectivity is particularly relevant as it is associated with a lower incidence of sexual side effects, which can be a significant concern for patients and impact adherence to treatment.
Timeline of Development and Regulatory Milestones
The journey of Kerendia to widespread availability in England has been marked by a series of regulatory approvals and evaluations. Bayer’s commitment to developing innovative treatments for cardiovascular and renal diseases has been evident throughout this process.
- Prior Approval for Chronic Kidney Disease: In 2023, NICE had already provided initial approval for Kerendia’s use in adult patients with chronic kidney disease (CKD) stages 3 or 4, specifically those with type 2 diabetes and evidence of albuminuria (the presence of blood protein in urine). This earlier endorsement demonstrated NICE’s recognition of Kerendia’s potential in managing conditions that often co-exist with or contribute to heart failure.
- NICE’s Final Draft Guidance: The recent recommendation for heart failure patients with preserved or mildly reduced ejection fraction represents a significant expansion of Kerendia’s approved indications within the NHS. The final draft guidance from NICE is expected in August 2026, paving the way for its formal integration into routine clinical practice.
- MHRA and NICE Aligned Pathway: The UK’s regulatory landscape for medicines has also seen recent evolution. In March 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) and NICE launched an aligned pathway designed to expedite the regulation of new medicines. This initiative aims to ensure that innovative treatments reach patients more quickly, potentially benefiting the rollout of Kerendia and similar future therapies.
Patient Eligibility and Estimated Impact
With NICE’s recommendation, an estimated 280,000 individuals across England are now likely to become eligible for treatment with Kerendia. This substantial number highlights the significant unmet need within the CHF patient population with preserved or mildly reduced ejection fraction. The condition’s prevalence, coupled with its impact on hospitalisation rates, underscores the urgent need for such therapeutic advancements.
The recommendation also positions Kerendia within a broader context of evolving heart failure management strategies. It will join other important treatment classes already recommended by NICE for this patient group, including SGLT2 inhibitors such as Jardiance (empagliflozin) from Boehringer Ingelheim and Eli Lilly, and Forxiga (dapagliflozin) from AstraZeneca, both of which received NICE approval for CHF with preserved or mildly reduced ejection fraction in 2023. The therapeutic armamentarium will also continue to include legacy MRAs and loop diuretics, providing clinicians with a comprehensive toolkit to manage fluid overload and other symptoms.
Expert Perspectives and Systemic Benefits
The NICE recommendation is viewed as a positive development by healthcare professionals and patient advocates alike. Helen Knight, NICE’s Director of Medicines Evaluation, articulated the potential multifaceted benefits of Kerendia. She stated that the drug not only holds the promise of enhancing patients’ quality of life but also offers the prospect of significant cost savings for the NHS. By reducing the likelihood of unplanned emergency hospital admissions, Kerendia can help to "save the NHS money and free up space," a crucial consideration for a healthcare system often operating under immense pressure.
This perspective aligns with the broader economic implications of managing chronic diseases. Effective treatment that prevents hospitalizations can lead to substantial reductions in healthcare expenditure, allowing resources to be redirected to other critical areas of patient care. For patients, avoiding hospital stays means a reduction in disruption to their lives, a decrease in the risk of hospital-acquired infections, and an overall improvement in their ability to manage their condition at home.
Broader Implications for Cardiovascular and Renal Health
The expanded use of Kerendia in England has implications that extend beyond immediate heart failure treatment. Given its proven efficacy in managing CKD associated with type 2 diabetes, its wider application in CHF could foster a more integrated approach to managing co-morbid cardiovascular and renal conditions. This holistic perspective is increasingly recognized as essential for optimizing patient outcomes and preventing the cascade of complications that often arise when these conditions are treated in isolation.
The success of Kerendia in the UK market will likely influence its adoption and accessibility in other healthcare systems globally. As regulatory bodies and healthcare providers observe its real-world effectiveness and economic benefits, similar recommendations and market access decisions may follow. This could lead to a significant shift in how mineralocorticoid receptor antagonists are utilized in the management of a broader spectrum of cardiovascular and renal diseases.
Future Outlook and Ongoing Research
While the NICE recommendation is a significant milestone, ongoing research and post-market surveillance will be crucial in further defining Kerendia’s long-term impact. Studies continue to explore the full spectrum of its benefits, including its potential to slow disease progression, reduce the incidence of major adverse cardiovascular events, and improve patient survival rates. The data gathered from real-world clinical practice in England will provide valuable insights into these areas.
The availability of a new, well-tolerated therapeutic option like Kerendia for heart failure patients with preserved or mildly reduced ejection fraction represents a tangible step forward in the fight against a prevalent and often devastating disease. As the NHS prepares to integrate this treatment into its formularies, the focus will be on ensuring equitable access for all eligible patients and maximizing the therapeutic potential of this innovative medicine to improve lives and reduce the burden on healthcare services.
